Login to Your Account



Pharma: Clinic Roundup


Wednesday, August 22, 2012
• Eisai Inc., of Woodcliff Lake, N.J., reported results from a final pivotal Phase III trial, showing that once-daily, adjunctive perampanel improved seizure control and was acceptably tolerated in subjects 12 and older with refractory partial-onset seizures.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription